An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART

Trial Profile

An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Cal-1 transduced T cells (Primary) ; Cal-1-transduced haematopoietic stem progenitor cells (Primary) ; Busulfan
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacogenomic
  • Sponsors Calimmune
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Nov 2016 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
    • 28 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top